Michael F. Murphy, MD, PhD

Authored Items
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
Kenneth LaPensee, PhD, MPH, Michael F. Murphy, MD, PhD, Thomas Lodise, PhD, PharmD
December 2018 Vol 11, No 9 in Business, Original Research
Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis
Gilbert L. Queeley, PhD, Michael F. Murphy, MD, PhD, Ellen S. Campbell, PhD
May 2018 Vol 11, No 3 in Clinical, Original Research
Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population
Jill R. Davis, MS, Bingcao Wu, MS, David M. Kern, PhD, Ozgur Tunceli, PhD, Kathleen M. Fox, PhD, John Horton, MS, Randall F. Legg, PharmD, MBA, Frank Trudo, MD, MBA, Michael F. Murphy, MD, PhD
April 2017 Vol 10, No 2 in Clinical, Original Research
Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator
Thanh-Nghia Nguyen, DrPH, MPH, MBA, Michael F. Murphy, MD, PhD, Jeffrey Trocio, MPH, Stacey Kowal, MS, Cheryl P. Ferrufino, Julie Munakata, MS, Dell South, PharmD
December 2016 Vol 9, No 9 in Business
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia
Marie-Hélène Lafeuille, MA, Michael F. Murphy, MD, PhD, Christian Frois, PhD, Michel Cloutier, PhD, Mei Sheng Duh, MPH, ScD, Patrick Lefebvre, MA, Jacqueline Pesa, PhD, MPH, Zoe Clancy, PharmD, John Fastenau, RPh, MPH, Mike Durkin, MSc
October 2016 Vol 9, No 7 in Clinical
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD
October 2015 Vol 8, No 7 in Business, Original Research
Demonstrating Value for Biosimilars: A Conceptual Framework
Sally Amanuel, MSc, MA, MBA, Michael Kleinrock, Paola Antonini, MD, PhD, Victoria Coutinho, MSc, PhD, Thomas Goss, PharmD, Zhihong Lai, PhD, Sotiris Rompas, Phd, Michael F. Murphy, MD, PhD
May 2015, Vol 8, No 3 in Business
Cardiovascular-Related Healthcare Resource Utilization and Costs in Patients with Hypertension Switching from Metoprolol to Nebivolol
Stephanie Chen, PhD, Michael F. Murphy, MD, PhD, An-Chen Fu, MS, BSPharm, Rahul Jain, PhD, Hiangkiat Tan, MS, BSPharm
April 2015, Vol 8, No 2 in Clinical
Current Challenges in Health Economic Modeling of Cancer Therapies: A Research Inquiry
Jeffrey D. Miller, MS, Michael F. Murphy, MD, PhD, Kathleen A. Foley, PhD, Mason W. Russell, MAPE
May 2014 Vol 7, No 3 in Business
Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil
Chamika Hawkins-Taylor, MHA, PhD, Michael F. Murphy, MD, PhD, Angeline M. Carlson, PhD
September 2013, Vol 6, No 7 in Business
The Economic Burden of Fragile X Syndrome: Healthcare Resource Utilization in the United States
Patricia Sacco, MPH, RPh, Gorana Capkun-Niggli, PhD, Xin Zhang, MS, Rosemary Jose, PhD, Michael F. Murphy, MD, PhD
March/April 2013 Vol 6, No 2 in Business
Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine
Demissie Alemayehu, PhD, Michael F. Murphy, MD, PhD, Joseph C. Cappelleri, PhD
July/August 2012, Vol 5, No 5 in Clinical
Utilization of Anticoagulation Therapy in Medicare Patients with Nonvalvular Atrial Fibrillation
Delete Delete, Jonah Broulette, Bruce S. Pyenson, FSA, MAAA, Kosuke Iwasaki, FIAJ, MAAA, Winghan Jacqueline Kwong, PharmD, PhD, Michael F. Murphy, MD, PhD
May/June 2012, Vol 5, No 3 in Business
Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting
Judy Kempf, PhD, Erin Buysman, MS, Diana Brixner, RPh, PhD, Michael F. Murphy, MD, PhD
September/October 2011 Volume 4, Number 6 in Business
Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
Henry J. Riordan, PhD, Atheer A. Kaddis, PharmD, Paola Antonini, MD, PhD, Michael F. Murphy, MD, PhD
September 2011, Vol 4, No 5 in Clinical
Postapproval Development Options in COPD: A Case Study in Value-Based Healthcare Systems
Paola Antonini, MD, PhD, Zhihong Lai, PhD, Michael F. Murphy, MD, PhD
January/February 2011, Vol 4, No 1 in Regulatory
A Wellness-Based Healthcare System for Chronic Diseases: Prevention, Intervention, and Innovation
Robert E. Henry, Kip Piper, MA, FACHE, F. Randy Vogenberg, PhD, FASHP, Thomas McCarter, MD, FACP, Farrah N. Daly, MD, MBA, Keri Cooper, Nirav R. Shah, MD,MPH, Lawton Robert Burns, PhD, MBA, Gene Reeder, RPh, PhD, Scott Gottlieb, MD, Toni Fera, BPharm, PharmD, Wayne M. Lednar, MD, PhD, Alberto M. Colombi, MD, MPH, Michael F. Murphy, MD, PhD, Gary M. Owens, MD, James T. Kenney, RPh, MBA, J. B. Jones, PhD, MBA, Walter F. Stewart, PhD, MPH
Supplements
Medicare Coverage Policies for Biologics: The Broad Gray Line
Michael F. Murphy, MD, PhD
April 2008, Vol 1, No 3 in Regulatory
Capnography Monitoring Enhances Safety of Postoperative Patient-Controlled Analgesia
Thomas McCarter, MD, FACP, Michael F. Murphy, MD, PhD, Zakir Shaik, MD, MHA, Keith Scarfo, DO, MS, Laura J. Thompson, RT(R), MBA
June 2008, Vol 1, No 5 in Clinical
When Novelty Is Not Enough
Michael F. Murphy, MD, PhD
March 2008, Vol 1, No 2 in Clinical
The 2007 Pharmaceutical and Biotech Pipeline Year-End Summary: What it Says About the State of the Art of Discovery & Development
Michael F. Murphy, MD, PhD
February 2008, Vol 1, No 1 in Industry Trends
Cost-Effectiveness of Second-Generation Antihistamines and Montelukast in Relieving Allergic Rhinitis Nasal Symptoms
Michael J. Goodman, PhD, Michael F. Murphy, MD, PhD, Mehul Jhaveri, PharmD, Kim Saverno, PhD, Kellie Meyer, PharmD, Brian Nightengale, PhD
October 2008, Vol 1, No 8 in Business
Pharmacogenomics and Drug Development
Michael F. Murphy, MD, PhD
March/April 2010, Vol 3, No 2 in Industry Trends
Last modified: April 12, 2019
SUBSCRIBE
Copyright © Amplity Medical Communications. All rights reserved.